AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05094505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control diet
Description: Control diet: diet plans will be individualized and energy-content prescriptions will be constant throughout the study to maintain the isocaloric control between diets. The planned macronutrient compositions will be 20% of energy from fat, 20% from protein and 60% from carbohydrates for the low-fat diet during the 8 weeks. Diets emphasis on low-glycemic index foods and limited saturated fat to 10% of energy. Participants will meet individually with a dietitian two times for 8 weeks and should start the dietary intervention along with the intervention with exercise.
Study NCT05094505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise in hypoxia
Description: Exercise at 3000m altitude, 3 sessions per week, during a 8-week period intervention and will consist in 60 min on an ergometer, of continuous moderate and high intensity interval training. . All exercise testing and training sessions will be carried out at the same time of day (± 2 hours) and visits will be separated by at least 48h of recovery.
Study NCT05094505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: Low carbohydrate diet: diet plans will be individualized and energy-content prescriptions will be constant throughout the study to maintain the isocaloric control between diets. The planned macronutrient compositions will be 40% of energy from fat, 20% from protein and 40% from carbohydrates for the low-fat diet during the 8 weeks. Diets emphasis on low-glycemic index foods and limited saturated fat to 10% of energy. Participants will meet individually with a dietitian two times for 8 weeks and should start the dietary intervention along with the intervention with exercise.
Study NCT04708925 — intervention group
Intervention type: OTHER
Intervention: conservative versus plasmapharesis therapy
Description: conservative versus plasmapharesis therapy
Study NCT06227078 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotaping
Description: Kinesiotaping is commonly used in sports medicine and rehabilitation settings. It is applied by trained professionals, such as physiotherapists or athletic trainers, who are skilled in assessing individual needs and determining the appropriate taping technique for specific conditions. The tape is typically worn for several days, allowing for continuous therapeutic effects.~It's important to note that while kinesiotaping has gained popularity, its effectiveness is still a subject of ongoing research, and its application should be part of a comprehensive treatment plan. Individual responses to kinesiotape may vary, and its use is often combined with other therapeutic interventions for optimal results.
Study NCT06227078 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiotaping
Description: Kinesiotaping is commonly used in sports medicine and rehabilitation settings. It is applied by trained professionals, such as physiotherapists or athletic trainers, who are skilled in assessing individual needs and determining the appropriate taping technique for specific conditions. The tape is typically worn for several days, allowing for continuous therapeutic effects.~It's important to note that while kinesiotaping has gained popularity, its effectiveness is still a subject of ongoing research, and its application should be part of a comprehensive treatment plan. Individual responses to kinesiotape may vary, and its use is often combined with other therapeutic interventions for optimal results.
Study NCT05344040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely Delivered and Supported Aerobic Walking Exercise Training
Description: This condition will include 16-weeks of remotely-delivered and supported aerobic walking exercise training based on guidelines for physical activity in persons with MS for general health benefits. Exercise intensities will be prescribed based on steps per exercise sessions from a waist-worn FitBit One™ (FitBit, Inc., San Francisco, CA).~The exercise program involves one-on-one semi-structured sessions with an MS exercise specialist (i.e., behavior coach) throughout the program. These sessions focus on exercise training guidance and oversight, discussion of the behavioral strategies of action planning and self-monitoring, and presentation and discussion of newsletters for optimizing exercise compliance.
Study NCT05344040 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remotely Delivered and Supported Stretching and Toning Exercise Training
Description: The active, non-aerobic exercise condition will involve stretching-and-toning activities. These activities will be based on a manual provided by the National Multiple Sclerosis Society. Participants will be provided with necessary exercise equipment (e.g., yoga mat, FitBit), an instructional DVD, and a manual, log-book, calendar, and prescription for the stretching program. This program will be supplemented with periodic newsletters delivered electronically that highlight principles of behavior change, and video-chats with a behavior coach that provide motivation and social accountability. These occur on the same timeline and frequency as in the walking condition, but focus on constructs for stretching.
Study NCT06590519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Date Seed Extract
Description: Intervention group participants will undergo a three-month intervention program. The Health Belief Model (HBM) will be the underlying theory to facilitate behaviour change.~The intervention group will receive a capsule of date-seed-powder. Each person should consume 5 grams (two capsules of date-seed powder)twice daily after meals for three months.~Assessments are carried out at the beginning of the study, one month and two months after the intervention on the effect of date-seed on glycaemic control,risk of cardiovascular, physical activity, daytime sleepiness and anthropometric measurements. Participants will be contacted twice a week to ensure that they are adhering to the rules.
Study NCT05790577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Nicotinamide vs Kligman Formula
Description: Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma
Study NCT06600113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and teaching of coping strategies
Description: the intervention consists of patient education for children, the same content delivered through either an educational game and storytelling
Study NCT06600113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and teaching of coping strategies
Description: the intervention consists of patient education for children, the same content delivered through either an educational game and storytelling
Study NCT06602375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The standard care (control) group will follow the plan of care determined by their treating dental provider. These decisions will be based on the clinical judgment of the dental provider and subject desires. Intervention may include, but is not limited to typical patient education, pharmacotherapy, oral splinting or occlusal device, cryo/thermotherapy recommendations, and exercise handouts.
Study NCT06602375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: The standard care (control) group will follow the plan of care determined by their treating dental provider. These decisions will be based on the clinical judgment of the dental provider and subject desires. Intervention may include, but is not limited to typical patient education, pharmacotherapy, oral splinting or occlusal device, cryo/thermotherapy recommendations, and exercise handouts.
Study NCT06602375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Description: Participants randomized to this group will receive individualized, tailored courses of physical therapy care. Interventions may be directed at the temporomandibular, cervical, and/or scapulothoracic regions based on subject clinical presentation and impairments. Manual therapy joint and soft tissue mobilizations may be used to address pain, mobility, and motor control. Motor control exercises may be used to promote relaxation, improve range of motion, and appropriate postures. Strengthening exercise, primarily directed to the cervical and scapulothoracic regions, may be implemented as appropriate. Stretching exercise may be used to address pain and mobility deficits. The interventions are intentionally pragmatic; study participants will receive treatment as they are comfortable and as recommended by the treating therapist.
Study NCT06589947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensified BP control
Description: Treatment goal in the intensified group will be lowering BP ≤60th pct.
Study NCT06589947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Standard treatment is to achieve BP levels \&lt;90th pct.
Study NCT06600880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuronavigation-guided single-element focused ultrasound transducer
Description: Non-invasive focused ultrasound-induced blood-brain barrier opening will be attempted using a single-element transducer, guided with a neuronavigation system.
Study NCT06600880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason
Description: New packages of Lumason microbubbles will be shipped from Bracco Diagnostics Inc. and will be used in conjunction with the ultrasound transducer to temporarily open the BBB. Lumason microbubbles will be freshly activated before treatment sonication and will be drawn using a 10-ml syringe to reach the desired dosage of 0.1mL/kg right before the intravenous injection.
Study NCT06600880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents
Description: A high-resolution MRI (with and without gadolinium (Dotarem) contrast agent) will be acquired prior to BBB opening on the GE SIGNATM Premier (3T) (same scanner as in the NHP study) for pre-treatment planning and screening purposes. Then, a second MRI (with and without gadolinium) will be acquired and read by a Board-Certified Radiologist immediately after the treatment sonication in order to assess the BBB opening and safety. Finally, a final follow-up MRI (with and without gadolinium) will be conducted 3 days (±1 day) after the treatment to confirm BBB closing and/or safety. This will be read by a Board-Certified Radiologist as well.~All MRI procedures will be performed at the CUIMC/Neurological Institute of New York.
Study NCT06600880 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: A first PET/CT scan with Amyvid (18F-Florbetapir) and MK-6240 (F18-Florquinitau) tracers will be performed on the SIEMENS Biograph 64 to assess the baseline amyloid plaque load and tau load before the treatment, respectively. Finally, two follow-up PET/CT scans will be conducted 3 weeks (±1 week) and 3 months (±2 weeks) post-treatment to assess amyloid plaque load (using Amyvid) and tau load (using MK-6240).
Study NCT06448832 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: An ultrasound examination of the musculature of the plantar muscle and long palmar muscle is performed to determine their presence or absence.
Study NCT06140706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: transcutaneous Spinal Cord Stimulation (tSCS)
Description: Neurostimulation for upper extremity training, delivered through video telehealth, 8 weeks of home use for (i) feasibility and (ii) potential functional improvement.
Study NCT06212401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients received dexmedetomidine as a bolus over 10 minutes in a dose of 1ug/kg followed by an infusion at the rate of 0.5ug/kg/hr
Study NCT06212401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofole
Description: Patients received ketofol 1mg/kg over 10 minutes followed by 50ug/kg/min of infusion
Study NCT05172427 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 14 days of EMI
Description: Following the intervention, participants will receive personalized prompts whenever they report elevated stress or anxiety. These prompts will be generated at the end of the intervention session, and will only be sent to individuals in the EMI condition.
Study NCT05172427 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Uncertainty reappraisal training
Description: CLUE consists of an hour long intervention, followed by a 2-week long EMI. During the hour long intervention session, participants will receive psychoeducation (i.e., defining uncertainty), discuss myths associated with uncertainty (e.g., if I do not plan things, they will go poorly), and discuss behavioral experiments that can be done to challenge uncertainty beliefs.
Study NCT05984004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl isotonic saline solution
Description: The placebo-control in the phase I study was a 0.9% NaCl isotonic saline solution. This nasal spray solution has no pharmacological effect, but is considered to have a cleansing effect on the nose, supporting the treatment of nasal symptoms in nasal pathology. The solution is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19). The solution is bottled in the same fully-sealed nasal spray device containing Bacillus subtilis DSM 32444 postbiotic, used for Sperovid.
Study NCT05984004 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis DSM32444, inactivated
Description: Postbiotic DSM32444 is manufactured by HURO BIOTECH Company as a drug-grade active pharmaceutical ingredient. The Class A medical device containing Postbiotic DSM32444 is called Sperovid, which is manufactured by Dong Duoc Viet under ISO 13485:2016 standards for medical device. Sperovid has registration number: 220000033/PCBA-LA
Study NCT06600880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amyvid
Description: Amyloid PET tracer Amyvid (18F- Florbetapir) will be stored in their original container with proper radiation shielding at 25 °C and only handled by properly trained personnel in the handling and administration of radioactive materials, which requires employing proper radiation protection procedures.
Study NCT06600880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6240
Description: \[18F\]MK-6240 will be synthesized, purified, and formulated at the local radiochemistry synthesis laboratory and will be administered as a sterile, pyrogen-free solution by IV injection. The radiotracer \[18F\]MK-6240 is supplied in a sterile, ready-to-use solution, direct from the Columbia University PET Center. It is supplied for a targeted calibration time, the precise volume to be administered at a given time can be calculated based on the decay of F-18. Only personnel properly trained in the handling and administration of radioactive materials should handle \[18F\]MK-6240. Usual radiation protection procedures should be used for handling radiotracers, including shielding (lead or tungsten containers/shields), and personal protective equipment including gloves. There are no specific procedures required for the handling of \[18F\]MK-6240. The expiry of \[18F\]MK-6240 is eight hours from the time at End of Synthesis (EOS).
Study NCT06600880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem
Description: FDA-approved medication. Dotarem will be handled in accordance with the CUMC Research Pharmacy procedures and NYP policy P168, Version 4. Dotarem will be used according to its labeling. 0.2 ml/kg.
Study NCT06600880 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood samples will be collected through an intravenous catheter or a finger prick during screening, on the day of the FUS treatment and the follow up examinations (week 3 and month 3). These samples will be processed to assess any blood content changes induced by the focused ultrasound treatment.
Study NCT06600880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UR5e
Description: Universal Robots robotic arm used for the accurate positioning of the neuronavigation-guided single-element focused ultrasound transducer with respect to the patient's head.
Study NCT06600880 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine test
Description: Urine test required following the MRI and PET Centers policy used clinically for pregnancy screening
Study NCT06588010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OM-89 [Uro-Vaxom® Capsule]
Description: 1st phase and 2nd phase : 1 capsule per day of OM-89 for 90 consecutive days followed by a period of 90 days without treatment, then one capsule per day of OM-89 for 10 consecutive days each month for three months.
Study NCT06588010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OM-89 [Uro-Vaxom® Capsule] OM-89 placebo [Uro-Vaxom® Capsule placebo]
Description: 1st phase: 1 capsule per day of placebo for 90 consecutive days followed by a period of 90 days without treatment, then one capsule per day of placebo for 10 consecutive days each month for three months.~Then 2nd phase: 1 capsule a day of OM-89, for 90 consecutive days followed by a period of 90 days without treatment, then one capsule a day of OM-89 6mg for 10 consecutive days each month for three months.
Study NCT06597682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral prednisone tablet treatment
Description: Oral prednisone tablet treatment, taking 40mg (8 tablets) daily, with a reduction of 1 tablet (5mg) per week for the first 2 weeks, followed by a reduction of 0.5 tablets (2.5mg) per week from the 3rd week onwards, for a total duration of 3 months.
Study NCT06597682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhalation treatment with budesonide/formoterol
Description: Inhalation treatment with budesonide/formoterol powder inhaler (160µg; 4.5µg), inhaled twice daily, for a total duration of 2 weeks.
Study NCT06597682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy with cognitive enhancer drugs and oral prednisone
Description: Combination therapy with cognitive enhancer drugs and oral prednisone , starting dose of prednisone is 1mg per kilogram of body weight, with a reduction of 1 tablet (5mg) every 2 weeks, for a total duration of 6 months.
Study NCT06597682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo (cornstarch tablets)
Description: Oral placebo (cornstarch tablets), taking 8 tablets daily, with a reduction of 1 tablet (5mg) per week for the first 2 weeks, followed by a reduction of 0.5 tablets (2.5mg) per week from the 3rd week onwards, for a total duration of 3 months.
Study NCT06597682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhalation of placebo (saline solution)
Description: Inhalation of placebo (saline solution), inhaled twice daily, for a total duration of 2 weeks.
Study NCT06597682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combination therapy with cognitive enhancer drugs and oral placebo (cornstarch tablets)
Description: Combination therapy with cognitive enhancer drugs and oral placebo (cornstarch tablets), starting dose of cornstarch tablets is 1mg per kilogram of body weight, with a reduction of 1 tablet (5mg) every 2 weeks, for a total duration of 6 months.
Study NCT06600932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMS
Description: TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.
Study NCT06600932 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: control group
Description: The control treatment is a sham-controlled procedure, in which participants will be exposed to the recorded sounds of TMS pulses but without real magnetic stimulation.
Study NCT06603415 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total thyroidectomy
Description: Total thyroidectomy (with preservation of bilateral recurrent laryngeal nerves and all parathroid glands) for histopathology
Study NCT06599411 — intervention group
Intervention type: OTHER
Intervention: Sampling
Description: Collection of an additional volume of blood Superficial skin biopsy Skin swab
Study NCT06599411 — intervention group
Intervention type: OTHER
Intervention: Sampling
Description: Collection of an additional volume of blood Preservation of post-operative skin remnants Skin swab
Study NCT06599528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-R (Test-Reference drug)
Description: T: SJ04 (Test drug) R: Ovidrel® (Referecne drug) 250 μg of SJ04 injection or Oviderl®, administered subcutaneously once at two week intervals.
Study NCT06599528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-T (Reference-Test drug)
Description: R: Ovidrel®(Referecne drug) T: SJ04 (Test drug) 250 μg of SJ04 or Oviderl®, administered subcutaneously once at two week intervals.
Study NCT06299475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online counseling and invitation
Description: Online counseling - An educational video including contraceptive models, four key questions and an effectiveness chart (the LOWE intervention material).~Invitation to a clinic - access by weblinks to a regional or national website
Study NCT06594601 — intervention group
Intervention type: PROCEDURE
Intervention: lung recruitment potential assessed by 3D EIT
Description: Patients were ventilated based on the ARDS-Net suggestions. The patients were kept at supine position. The lung recruitment potential assessed by 3D EIT was as follows:~1. All patients were under pressure control mode (driving pressure 12-15 cmH2O with a tidal volume of 6-8 ml/kg predicted body weight, respiration rate12-15 bpm).~2. PEEP was switched to a zero end-expiratory pressure (ZEEP) for 10 min, and FiO2 was titrated to obtain peripheral oxygen saturation (SpO2 ) \&gt; 90%.~3. PEEP was stepwise increase from 0 to 15 cmH2O PEEP in steps of 5cm H2O every 3min.And 3D EIT was used to assess lung recruitment potential.